U.S. Environmental Protection Agency/Office of Research & Development/Center for Public Health and Environmental Assessment, Research Triangle Park, NC, USA.
U.S. Environmental Protection Agency/Office of Research & Development/Center for Environmental Measurement and Modeling, Research Triangle Park, NC, USA.
Environ Int. 2022 Feb;160:107056. doi: 10.1016/j.envint.2021.107056. Epub 2021 Dec 22.
Nafion byproduct 2 (NBP2) is a polyfluoroalkyl ether sulfonic acid that was recently detected in surface water, drinking water, and human serum samples from monitoring studies in North Carolina, USA. We orally exposed pregnant Sprague-Dawley rats to NBP2 from gestation day (GD) 14-18 (0.1-30 mg/kg/d), GD17-21, and GD8 to postnatal day (PND) 2 (0.3-30 mg/kg/d) to characterize maternal, fetal, and postnatal effects. GD14-18 exposures were also conducted with perfluorooctane sulfonate (PFOS) for comparison to NBP2, as well as data previously published for hexafluoropropylene oxide-dimer acid (HFPO-DA or GenX). NBP2 produced stillbirth (30 mg/kg), reduced pup survival shortly after birth (10 mg/kg), and reduced pup body weight (10 mg/kg). Histopathological evaluation identified reduced glycogen stores in newborn pup livers and hepatocyte hypertrophy in maternal livers at ≥ 10 mg/kg. Exposure to NBP2 from GD14-18 reduced maternal serum total T and cholesterol concentrations (30 mg/kg). Maternal, fetal, and neonatal liver gene expression was investigated using RT-qPCR pathway arrays, while maternal and fetal livers were also analyzed using TempO-Seq transcriptomic profiling. Overall, there was limited alteration of genes in maternal or F1 livers from NBP2 exposure with significant changes mostly occurring in the top dose group (30 mg/kg) associated with lipid and carbohydrate metabolism. Metabolomic profiling indicated elevated maternal bile acids for NBP2, but not HFPO-DA or PFOS, while all three reduced 3-indolepropionic acid. Maternal and fetal serum and liver NBP2 concentrations were similar to PFOS, but ∼10-30-fold greater than HFPO-DA concentrations at a given maternal oral dose. NBP2 is a developmental toxicant in the rat, producing neonatal mortality, reduced pup body weight, reduced pup liver glycogen, reduced maternal thyroid hormones, and altered maternal and offspring lipid and carbohydrate metabolism similar to other studied PFAS, with oral toxicity for pup loss that is slightly less potent than PFOS but more potent than HFPO-DA.
Nafion 副产物 2(NBP2)是一种聚全氟烷氧基磺酸,最近在美国北卡罗来纳州的监测研究中在地表水、饮用水和人血清样本中被检测到。我们通过口服方式使妊娠 Sprague-Dawley 大鼠在妊娠第 14-18 天(0.1-30mg/kg/d)、妊娠第 17-21 天和第 8 天到产后第 2 天(0.3-30mg/kg/d)接受 NBP2 暴露,以表征母体、胎儿和产后的影响。还进行了妊娠第 14-18 天的 NBP2 暴露与全氟辛烷磺酸(PFOS)的比较,以及之前发表的六氟丙烯氧化物二聚酸(HFPO-DA 或 GenX)的数据。NBP2 导致死胎(30mg/kg)、出生后不久幼仔存活率降低(10mg/kg)和幼仔体重降低(10mg/kg)。组织病理学评估发现,≥10mg/kg 时新生幼仔肝脏中的糖原储存减少,母体肝脏中的肝细胞肥大。从妊娠第 14-18 天开始接触 NBP2 会降低母体血清总 T 和胆固醇浓度(30mg/kg)。使用 RT-qPCR 途径阵列研究了 NBP2 暴露对母体、胎儿和新生儿肝脏基因表达的影响,同时还使用 TempO-Seq 转录组谱分析了母体和胎儿肝脏。总体而言,NBP2 暴露对母体或 F1 肝脏中的基因改变有限,只有在高剂量组(30mg/kg)中才会发生与脂质和碳水化合物代谢相关的显著变化。代谢组学分析表明,NBP2 会升高母体胆汁酸,但 HFPO-DA 或 PFOS 不会,而这三种物质都会降低 3-吲哚丙酸。母体和胎儿血清和肝脏中的 NBP2 浓度与 PFOS 相似,但在相同的母体口服剂量下,约为 HFPO-DA 浓度的 10-30 倍。NBP2 是一种在大鼠中具有发育毒性的物质,可导致新生仔死亡、幼仔体重减轻、幼仔肝脏糖原减少、母体甲状腺激素减少,并改变母体和后代的脂质和碳水化合物代谢,与其他研究过的 PFAS 相似,其对幼仔丢失的口服毒性作用略低于 PFOS,但强于 HFPO-DA。